Validation of the Spanish version of the Oxford Cognitive Screen (S-OCS): psychometric properties of a short cognitive stroke-specific screening tool.
CONCLUSION:: Our findings support that the Spanish version of the Oxford Cognitive Screen is a reliable and valid tool for screening cognitive impairments in subacute stroke patients. PMID: 30563369 [PubMed - as supplied by publisher]
Our United Council of Neurological Subspecialties (UCNS)-accredited program is offering a one- or two-year fellowship position beginning immediately. Our fellowship goal is to train exceptional and well-rounded neurointensivists who excel in patient care, research, and education. Fellows gain clinical experience though rotating in our busy contemporary neurocritical ICU and the neurocritical care consult service in our certified Comprehensive Stroke and Level 1 Trauma Center... Read more
Older adults prescribed stimulant medications appear to be at an elevated risk of cardiovascular problems in the first 30 days after beginning the treatment, according to astudy published today inJAMA Network Open. However, these risks decrease over time, with no evidence of increased cardiovascular risk at six months and one year after initiating treatment.“Although stimulants are most commonly used among children and youth for the treatment of attention-deficit/hyperactivity disorder (ADHD), an increase in stimulant use among older adults in recent years has been observed,” wrote Mina Tadrous, PharmD., Ph.D.,...
ConclusionsA significant number of patients with AF hospitalized for bleeding were discharged with no plan for stroke prophylaxis. Despite its safety and efficacy, LAAO appears to be an underutilized alternative in AF patients with high bleeding risk.
Notice NOT-NS-22-034 from the NIH Guide for Grants and Contracts
Notice NOT-NS-22-035 from the NIH Guide for Grants and Contracts
Notice NOT-NS-22-036 from the NIH Guide for Grants and Contracts
Notice NOT-NS-22-037 from the NIH Guide for Grants and Contracts
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to...
Condition: Ischemic Stroke Intervention: Sponsors: University Hospital, Basel, Switzerland; Swiss National Science Foundation Recruiting
Condition: Stroke, Acute Ischemic Interventions: Drug: Mechanical thrombectomy; Drug: medical treatment Sponsor: Assiut University Not yet recruiting